Among patients with PPF, those treated with 60 mg of admilparant showed significant decreases in periostin, ferritin, and ...
Medical Xpress on MSN22h
Fibrosis lacks treatments and methods of reversal: Study pinpoints a promising target for drug therapy"We sought to identify alternative ways to inhibit TGFβ signaling using human hepatic stellate cells and macrophages from ...
Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of ...
A research group from Ningbo Institute of Materials Technology and Engineering (NIMTE) of the Chinese Academy of Sciences ...
Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...
In addition to pulmonary fibrosis, columnist Ann Reynoso is now also dealing with sleep apnea — both of which affect her ...
Boehringer's phase 3 lung fibrosis trial hits primary endpoint, teeing up filings for Ofev successor
Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...
The Phase III trial evaluating nerandomilast as a treatment for idiopathic pulmonary fibrosis met its primary endpoint.
We quantified the proportion of diagnoses of pulmonary fibrosis (PF) among 25 136 people with lung cancer and 250 583 matched ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback